GE Healthcare believes measuring molecular function is a high unmet medical need. As an example, the use of Positron Emission Tomography (PET) with FDG is experiencing exploding growth across all geographies. PET, SPECT and potentially optical imaging procedures require enhancing agents to achive their potential to measure molecular function. This represents for the first time, the possibility to visualize specific processes / characteristics of a cancer cell.

GE Healthcare is developing or seeking products for the following areas of cancer:

• General functional markers for measuring a general tumor characteristic
• Shallow optical imaging opportunities in digestive, lung and bladder cancers
• Tumor Viability Evaluation

High priorities are agents that target cancers of the:

• Prostate
• Breast
• GI tract
• Lung

• Cardiology
• Neurology
• Oncology
• Internal Medicine